Insights on Patent

On August 28, New York Partner and Chairperson of the USPTO’s Patent Public Advisory Committee, Marylee Jenkins, was quoted in Law360 regarding the week-long outage of the USPTO’s online patent filing system earlier in the month.

About nine months ago, the en banc Federal Circuit decided in Aqua Products v. Matal that the America Invents Act and related regulatory landscape place the burden in an inter partes review on the non-movant petitioner to disprove patentability of a patent owner’s proposed motion to amend.

Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace.

In WesternGeco LLC v. ION Geophysical Corp., the Supreme Court recently held that patent holders can recover lost foreign profits for patent infringement under 35 U.S.C. § 271(f).

Schiff Hardin is proud to announce that Intellectual Property Practice Group Co-Leader Imron Aly has been recognized in the seventh edition of IAM Patent 1000.

Intellectual Property Group Co-Leader Imron Aly was quoted on a U.S. Supreme Court patent ruling in Oil States Energy Services LLC v. Greene’s Energy Group LLC that upheld the America Invents Act (AIA) review system for challenging patents as constitutional, with some key operation changes.

Schiff Hardin LLP is pleased to announce that three of its practice groups have been recognized for the third consecutive year by The Legal 500 United States 2018 guide, a nationwide analysis of law firms with input from more than 300,000 corporate counsel on which firms provide the most cutting-edge and innovative advice.

The 2018 edition of Legal 500 US has rated 50 Arent Fox LLP attorneys as national leaders in their field. In addition, 18 of the firm’s practice areas were ranked among the best in the country, including new recognition for the firm’s Trademark Litigation and White Collar groups.

Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel explained why some biosimilar companies engaged in Biologics Price Competition and Innovation Act (BPCIA) litigation may choose to settle.

LOS ANGELES, CA — Craig Gelfound, head of Arent Fox LLP’s Intellectual Property practice in Los Angeles, has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, with 2018 marking his eighth consecutive year of this recognition.

Schiff Hardin has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category.

Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel was featured on the ongoing Biologics Price Competition and Innovation Act (BPCIA) Litigation he is watching.

Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly examines how current Hatch-Waxman legal proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.

Schiff Hardin is pleased to announce that four practice areas and 22 attorneys have been recognized in the 2018 edition of Chambers USA, a leading legal industry ranking.

Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly forecast the significance of the U.S. Supreme Court ruling in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, and how it could impact future patent challenge cases.

Arent Fox is pleased to announce the launch of a new Blockchain group that pulls together attorneys from a number of the firm’s top practices to help clients navigate this emerging technology.

Arent Fox Partner Wib Chesser, in an article published in the April 2018 issue of Intellectual Property Magazine, offers best practices to companies as they enter a business transaction.

This Special Report is written by Helen Ji, Schiff Hardin LLP associate, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals, and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines.

Partner Kevin Nelson was quoted on the Knowledge Ecology International’s urging of the National Institutes of Health (NIH) to leverage the Bayh-Dole Act in order to combat rising drug prices.

Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.

Personalized medicine patent claims have been under assault since the Supreme Court’s Mayo v. Prometheus decision.

This past November, the US Supreme Court heard oral arguments in a case that may dramatically affect how patents covering biologic drugs are litigated: Oil States Energy Services, LLC v Greene’s Energy Group, LLC.

Schiff Hardin is pleased to announce that 18 of the firm’s attorneys have been named to the 2018 Emerging Lawyers Network.

This year brought us very significant changes in patent jurisprudence from the Supreme Court and Federal Circuit affecting Chemical & Life Sciences patent practice.

For patent practitioners, this year packed in a lot of activity.